Cargando…
1953. VE303, a Rationally Designed Bacterial Consortium for Prevention of Recurrent Clostridioides difficile (C. Difficile) infection (rCDI), Stably Restores the Gut Microbiota After Vancomycin (vanco)-Induced Dysbiosis in Adult Healthy Volunteers (HV)
BACKGROUND: Gut microbiota alterations and resulting changes in metabolites involved in colonization resistance and host responses, including bile acids (BA) and short-chain fatty acids (SCFA), are hallmarks of C. difficile infection. Reduction in rCDI was shown with fecal microbiota transplants (FM...
Autores principales: | Bobilev, Dmitri, Bhattarai, Shakti, Menon, Rajita, Klein, Brian, Reddy, Shilpa, Olle, Bernat, Roberts, Bruce, Bucci, Vanni, Norman, Jason |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809015/ http://dx.doi.org/10.1093/ofid/ofz359.130 |
Ejemplares similares
-
2140. Biological Features of Response to VE303, a Defined Bacterial Consortium, in Patients with Clostridioides difficile Infection (CDI): Results from the Phase 2 CONSORTIUM Study
por: Menon, Rajita, et al.
Publicado: (2023) -
Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI)
por: Kullar, Ravina, et al.
Publicado: (2020) -
SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)
por: Khanna, Sahil, et al.
Publicado: (2022) -
Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)
por: Golan, Yoav, et al.
Publicado: (2017) -
Applying fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infections (rCDI) in children
por: Fareed, Shaaz, et al.
Publicado: (2018)